Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/24/2017 03/27/2017 03/28/2017 03/29/2017 03/30/2017 Date
373(c) 383.68(c) 382.55(c) 394.14(c) 387.2699 Last
881 363 1 386 403 1 651 254 1 945 473 590 148 Volume
+2.19% +2.86% -0.29% +3.03% -1.74% Change
More quotes
Financials ($)
Sales 2017 5 477 M
EBIT 2017 2 150 M
Net income 2017 1 006 M
Finance 2017 1 797 M
Yield 2017 -
Sales 2018 6 129 M
EBIT 2018 2 593 M
Net income 2018 1 259 M
Finance 2018 4 263 M
Yield 2018 -
P/E ratio 2017 46,43
P/E ratio 2018 36,47
EV / Sales2017 7,31x
EV / Sales2018 6,13x
Capitalization 41 811 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
03/29 SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
03/29 SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/23 REGENERON PHARMACEUTICALS : New Findings from Regeneron Pharmaceuticals Inc. in ..
03/23 REGENERON PHARMACEUTICALS : Teen Scientist Researches New Approach to Neurologic..
03/23 REGENERON PHARMACEUTICALS : Patent Issued for Angiopoietin-Based Interventions f..
03/23 REGENERON PHARMACEUTICALS : U.K. Biobank, Regeneron and GSK Announce Largest Gen..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03:16a$REGN - Regeneron Pharmaceuticals Inc #REGN Given Buy Rating at BTIG Research.. 
02:26aRegeneron Pharmaceuticals's buy rating reiterated at BTIG Research. $460.00 P.. 
02:14aLargest gainers today 3/29/2017 on my Watch List were: $UA $AMZN $AYI $REGN $.. 
03/29FDA Approves Regeneron Pharmaceuticals (REGN) And Sanofi's (SNY) Dupixent - S.. 
03/29$REGN 400+ 
More tweets
Qtime:94
News from SeekingAlpha
03/29 FDA Approves Regeneron Pharmaceuticals (REGN) And Sanofi's (SNY) Dupixent - S..
03/28 FDA OKs Regeneron and Sanofi's dermatitis med Dupixent
03/24 Industry And Dark Pool Traders Bearish On Amgen
03/24 FDA Decision For Dupixent As Novartis Drives Its CAR-T
03/21 Sanofi, Regeneron sue Amgen over eczema drug
Advertisement
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 423 $
Spread / Average Target 7,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..7.37%41 811
AMGEN, INC.11.52%120 086
CELGENE CORPORATION7.21%96 538
GILEAD SCIENCES, INC.-6.07%87 925
ACTELION LTD24.44%30 002
VERTEX PHARMACEUTICALS..46.61%26 834
More Results